Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24047165 | 0.85 | HRH3 (0.59) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL24047167 | 0.83 | HRH3 (0.62) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL21884103 | 0.81 | HRH3 (0.65) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL24047673 | 0.81 | SIGMAR1 (0.54) | HRH3 | |
| SCHEMBL15467001 | 0.80 | HRH3 (0.87) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL10159880 | 0.78 | HRH3 (0.65) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL4547887 | 0.78 | HRH3 (0.65) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL19441606 | 0.77 | HRH3 (0.62) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL19441582 | 0.77 | HRH3 (0.62) | HRH3SMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL11864 | 0.75 | HRH3 (0.71) | HRH3SMN1; SMN2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203081-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2021236911-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203081-A1 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | NPEPPS, TLR7, ASNS | HRH3 3843/4885SMN1; SMN2 2150/4885NOS3 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.